Regulatory Affairs Market Size, Share & Trends Analysis Report By Service, By Categories (Biologics, Drugs), By Indication, By Product Stage, By End Use, By Service Providers, By Company Size, By Region, And Segment Forecasts, 2021 - 2028

Table of Contents

Chapter 1 Methodology and Scope
                   1.1 Market Segmentation & Scope
                       1.1.1 Estimates and forecast timeline
                   1.2 Research Methodology
                   1.3 Information Procurement
                       1.3.1 Purchased database
                       1.3.2 GVR’s internal database
                       1.3.3 Secondary sources
                       1.3.4 Primary research
                       1.3.5 Details of primary research
                   1.4 Information or Data Analysis
                       1.4.1 Data analysis models
                   1.5 Market Formulation & Validation
                   1.6 Region Wise Market Calculation
                       1.6.1 Region-wise market: Base estimates
                       1.6.2 Global market: CAGR calculation
                   1.7 List of Secondary Sources
                   1.8 Objectives
                       1.8.1 Objective - 1: Understanding market dynamics
                       1.8.2 Objective - 2: Understanding market estimates and forecasts
                       1.8.3 Objective - 3: Understanding attributes such as strategy framework and competitor categorization
                       1.8.4 Objective - 4: Understanding the key service and application scopes
Chapter 2 Executive Summary
                   2.1 Market Outlook
Chapter 3 Regulatory Affairs Market: Variables, Trends, & Scope
                   3.1 Market Segmentation and Scope
                   3.2 Market Dynamics
                       3.2.1 Market driver analysis
                           3.2.1.1 Changing regulatory landscape
                           3.2.1.2 Entry of companies in the global market
                           3.2.1.3 Life science companies focusing on their core competencies
                           3.2.1.4 Economic and competitive pressures
                           3.2.1.5 Demand for faster approval process for breakthrough drugs and devices
                           3.2.1.6 Growth in emerging areas such as personalized medicine, biosimilars, and orphan drugs
                       3.2.2 Market restraint analysis
                           3.2.2.1 Risk associated with data security
                           3.2.2.2 Monitoring issues and lack of standardization
                   3.3 Penetration & Growth Prospect Mapping
                   3.4 Industry Challenges
                       3.4.1 Managing relationships
                   3.5 Major Deals and Strategic Alliances Analysis
                   3.6 Major Deals and Strategic Alliances Analysis (Biotech & ATMPs)
                   3.7 Regulatory affairs: Market Analysis Tools
                       3.7.1 SWOT
                       3.7.2 Industry analysis - Porter’s
                       3.7.3 PESTEL analysis
Chapter 4 Regulatory affairs Market: Service Segment Analysis
                   4.1 Regulatory affairs: Service Market Share Analysis, 2020 & 2028
                   4.2 Regulatory Consulting
                       4.2.1 Regulatory consulting market, 2016 - 2028 (USD Million)
                   4.3 Legal Representation
                       4.3.1 Legal representation market, 2016 - 2028 (USD Million)
                   4.4 Regulatory Writing and Publishing
                       4.4.1 Regulatory writing and publishing market, 2016 - 2028 (USD Million)
                   4.5 Product Registration and Clinical Trial Application
                       4.5.1 Product registration and clinical trial application market, 2016 - 2028 (USD Million)
                   4.6 Other Regulatory Services
                       4.6.1 Other regulatory services market, 2016 - 2028 (USD Million)
Chapter 5 Regulatory Affairs Market: Service Provider Segment Analysis
                   5.1 Regulatory Affairs: Service Provider Market Share Analysis, 2020 & 2028
                   5.2 In-house
                       5.2.1 In-house regulatory affairs market, 2016 - 2028 (USD Million)
                   5.3 Outsourcing
                       5.3.1 Outsourcing market, 2016 - 2028 (USD Million)
Chapter 6 Regulatory Affairs Market: Company Size Segment Analysis
                   6.1 Regulatory Affairs: Company Size Market Share Analysis, 2020 & 2028
                   6.2 Small Sized
                       6.2.1 Small companies based regulatory affairs market, 2016 - 2028 (USD Million)
                   6.3 Medium Sized
                       6.3.1 Medium-sized companies based regulatory affairs market, 2016 - 2028 (USD Million)
                   6.4 Large Companies
                       6.4.1 Large companies based regulatory affairs market, 2016 - 2028 (USD Million)
Chapter 7 Regulatory Affairs Market: Categories Segment Analysis
                   7.1 Regulatory Affairs: Categories Market Share Analysis, 2020 & 2028
                   7.2 Drugs
                       7.2.1 Drugs based regulatory affairs market, 2016 - 2028 (USD Million)
                           7.2.1.1 Innovator drugs based regulatory affairs market, 2016 - 2028 (USD Million)
                               7.2.1.1.1 Preclinical drugs based regulatory affairs market, 2016 - 2028 (USD Million)
                               7.2.1.1.2 Clinical drugs based regulatory affairs market, 2016 - 2028 (USD Million)
                               7.2.1.1.3 Post market drugs based regulatory affairs market, 2016 - 2028 (USD Million)
                           7.2.1.2 Generic drugs based regulatory affairs market, 2016 - 2028 (USD Million)
                               7.2.1.2.1 Preclinical drugs based regulatory affairs market, 2016 - 2028 (USD Million)
                               7.2.1.2.2 Clinical drugs based regulatory affairs market, 2016 - 2028 (USD Million)
                               7.2.1.2.3 Post market drugs based regulatory affairs market, 2016 - 2028 (USD Million)
                   7.3 Biologics
                       7.3.1 Biologics based regulatory affairs market, 2016 - 2028 (USD Million)
                           7.3.1.1 Biotech based regulatory affairs market, 2016 - 2028 (USD Million)
                               7.3.1.1.1 Preclinical drugs based regulatory affairs market, 2016 - 2028 (USD Million)
                               7.3.1.1.2 Clinical based regulatory affairs market, 2016 - 2028 (USD Million)
                               7.3.1.1.3 Post market based regulatory affairs market, 2016 - 2028 (USD Million)
                           7.3.1.2 ATMP based regulatory affairs market, 2016 - 2028 (USD Million)
                               7.3.1.2.1 Preclinical based regulatory affairs market, 2016 - 2028 (USD Million)
                               7.3.1.2.2 Clinical based regulatory affairs market, 2016 - 2028 (USD Million)
                               7.3.1.2.3 Post market based regulatory affairs market, 2016 - 2028 (USD Million)
                           7.3.1.3 Biosimilar based regulatory affairs market, 2016 - 2028 (USD Million)
                               7.3.1.3.1 Preclinical based regulatory affairs market, 2016 - 2028 (USD Million)
                               7.3.1.3.2 Clinical based regulatory affairs market, 2016 - 2028 (USD Million)
                               7.3.1.3.3 Post market based regulatory affairs market, 2016 - 2028 (USD Million)
                   7.4 Medical Devices
                       7.4.1 Medical devices based regulatory affairs market, 2016 - 2028 (USD Million)
                           7.4.1.1 Diagnostic based regulatory affairs market, 2016 - 2028 (USD Million)
                               7.4.1.1.1 Preclinical based regulatory affairs market, 2016 - 2028 (USD Million)
                               7.4.1.1.2 Clinical based regulatory affairs market, 2016 - 2028 (USD Million)
                               7.4.1.1.3 Post market based regulatory affairs market, 2016 - 2028 (USD Million)
                           7.4.1.2 Therapeutic based regulatory affairs market, 2016 - 2028 (USD Million)
                               7.4.1.2.1 Preclinical based regulatory affairs market, 2016 - 2028 (USD Million)
                               7.4.1.2.2 Clinical based regulatory affairs market, 2016 - 2028 (USD Million)
                               7.4.1.2.3 Post market based regulatory affairs market, 2016 - 2028 (USD Million)
Chapter 8 Regulatory Affairs Market: Product Stage Segment Analysis
                   8.1 Regulatory Affairs: Product Stage Market Share Analysis, 2020 & 2028
                   8.2 Preclinical
                       8.2.1 Preclinical based regulatory affairs market, 2016 - 2028 (USD Million)
                   8.3 Clinical
                       8.3.1 clinical based regulatory affairs market, 2016 - 2028 (USD Million)
                   8.4 PMA
                       8.4.1 PMA based regulatory affairs market, 2016 - 2028 (USD Million)
Chapter 9 Regulatory Affairs Market: Indication Segment Analysis
                   9.1 Regulatory affairs: Indication Market Share Analysis, 2020 & 2028
                   9.2 Oncology
                       9.2.1 Oncology based regulatory affairs market, 2016 - 2028 (USD Million)
                   9.3 Neurology
                       9.3.1 Neurology based regulatory affairs market, 2016 - 2028 (USD Million)
                   9.4 Cardiology
                       9.4.1 cardiology based regulatory affairs market, 2016 - 2028 (USD Million)
                   9.5 Immunology
                       9.5.1 Immunology indication based regulatory affairs market, 2016 - 2028 (USD Million)
                   9.6 Other Indications
                       9.6.1 Other indication based regulatory affairs market, 2016 - 2028 (USD Million)
Chapter 10 Regulatory Affairs Market: End-use Segment Analysis
                   10.1 Regulatory affairs: End-use Market Share Analysis, 2020 & 2028
                   10.2 Medical Device Companies
                       10.2.1 Medical device companies market, 2016 - 2028 (USD Million)
                   10.3 Pharmaceutical Companies
                       10.3.1 Pharmaceutical companies market, 2016 - 2028 (USD Million)
                   10.4 Biotechnology Companies
                       10.4.1 Biotechnology companies market, 2016 - 2028 (USD Million)
Chapter 11 Regulatory Affairs Market: Regional Analysis
                   11.1 Regulatory affairs: Regional Market Share Analysis, 2020 & 2028
                   11.2 North America
                       11.2.1 North America regulatory affairs market, 2016 - 2028 (USD Million)
                       11.2.2 U.S.
                           11.2.2.1 U.S. Regulatory affairs market, 2016 - 2028 (USD Million)
                       11.2.3 Canada
                           11.2.3.1 Canada regulatory affairs market, 2016 - 2028 (USD Million)
                   11.3 Europe
                       11.3.1 Europe regulatory affairs market, 2016 - 2028 (USD Million)
                       11.3.2 U.K.
                           11.3.2.1 U.K. regulatory affairs market, 2016 - 2028 (USD Million)
                       11.3.3 Germany
                           11.3.3.1 Germany regulatory affairs market, 2016 - 2028 (USD Million)
                       11.3.4 France
                           11.3.4.1 France regulatory affairs market, 2016 - 2028 (USD Million)
                       11.3.5 Italy
                           11.3.5.1 Italy regulatory affairs market, 2016 - 2028 (USD Million)
                       11.3.6 Spain
                           11.3.6.1 Spain regulatory affairs market, 2016 - 2028 (USD Million)
                       11.3.7 Russia
                           11.3.7.1 Russia regulatory affairs market, 2016 - 2028 (USD Million)
                       11.3.8 Turkey
                           11.3.8.1 Turkey regulatory affairs market, 2016 - 2028 (USD Million)
                       11.3.9 Netherlands
                           11.3.9.1 Netherlands regulatory affairs market, 2016 - 2028 (USD Million)
                       11.3.10 Switzerland
                           11.3.10.1 Switzerland regulatory affairs market, 2016 - 2028 (USD Million)
                       11.3.11 Sweden
                           11.3.11.1 Sweden regulatory affairs market, 2016 - 2028 (USD Million)
                   11.4 Asia Pacific
                       11.4.1 Asia Pacific regulatory affairs market, 2016 - 2028 (USD Million)
                       11.4.2 Japan
                           11.4.2.1 Japan regulatory affairs market, 2016 - 2028 (USD Million)
                       11.4.3 China
                           11.4.3.1 China regulatory affairs market, 2016 - 2028 (USD Million)
                       11.4.4 India
                           11.4.4.1 India regulatory affairs market, 2016 - 2028 (USD Million)
                       11.4.5 Australia
                           11.4.5.1 Australia regulatory affairs market, 2016 - 2028 (USD Million)
                       11.4.6 South Korea
                           11.4.6.1 South Korea regulatory affairs market, 2016 - 2028 (USD Million)
                       11.4.7 Indonesia
                           11.4.7.1 Indonesia regulatory affairs market, 2016 - 2028 (USD Million)
                       11.4.8 Malaysia
                           11.4.8.1 Malaysia regulatory affairs market, 2016 - 2028 (USD Million)
                       11.4.9 Singapore
                           11.4.9.1 Singapore regulatory affairs market, 2016 - 2028 (USD Million)
                       11.4.10 Thailand
                           11.4.10.1 Thailand regulatory affairs market, 2016 - 2028 (USD Million)
                       11.4.11 Taiwan
                           11.4.11.1 Taiwan regulatory affairs market, 2016 - 2028 (USD Million)
                   11.5 Latin America
                       11.5.1 Latin America regulatory affairs market, 2016 - 2028 (USD Million)
                       11.5.2 Brazil
                           11.5.2.1 Brazil regulatory affairs market, 2016 - 2028 (USD Million)
                       11.5.3 Mexico
                           11.5.3.1 Mexico regulatory affairs market, 2016 - 2028 (USD Million)
                       11.5.4 Argentina
                           11.5.4.1 Argentina regulatory affairs market, 2016 - 2028 (USD Million)
                       11.5.5 Colombia
                           11.5.5.1 Colombia regulatory affairs market, 2016 - 2028 (USD Million)
                       11.5.6 Chile
                           11.5.6.1 Chile regulatory affairs market, 2016 - 2028 (USD Million)
                   11.6 MEA
                       11.6.1 MEA regulatory affairs market, 2016 - 2028 (USD Million)
                       11.6.2 South Africa
                           11.6.2.1 South Africa regulatory affairs market, 2016 - 2028 (USD Million)
                       11.6.3 Saudi Arabia
                           11.6.3.1 Saudi Arabia regulatory affairs market, 2016 - 2028 (USD Million)
                       11.6.4 UAE
                           11.6.4.1 UAE regulatory affairs market, 2016 - 2028 (USD Million)
                       11.6.5 Egypt
                           11.6.5.1 Egypt regulatory affairs market, 2016 - 2028 (USD Million)
                       11.6.6 Israel
                           11.6.6.1 Israel regulatory affairs market, 2016 - 2028 (USD Million)
Chapter 12 Company Profiles
                   12.1 Accell Clinical Research, LLC.
                       12.1.1 Company overview
                       12.1.2 Financial performance
                       12.1.3 Organization structure & team composition
                           12.1.3.1 Team composition
                       12.1.4 Service benchmarking
                       12.1.5 Geographic presence
                       12.1.6 Strategic initiatives
                       12.1.7 SWOT
                   12.2 GenPact Ltd.
                       12.2.1 Company overview
                       12.2.2 Financial performance
                       12.2.3 Organization structure & team composition
                           12.2.3.1 Team composition
                       12.2.4 Service benchmarking
                       12.2.5 Geographic presence
                       12.2.6 Strategic initiatives
                       12.2.7 SWOT
                   12.3 Criterium, Inc.
                       12.3.1 Company overview
                       12.3.2 Financial performance
                       12.3.3 Organization structure & team composition
                           12.3.3.1 Team composition
                       12.3.4 Service benchmarking
                       12.3.5 Geographic presence
                       12.3.6 SWOT
                   12.4 PRA Health Sciences
                       12.4.1 Company overview
                       12.4.2 Financial performance
                       12.4.3 Organization structure & team composition
                           12.4.3.1 Team composition
                       12.4.4 Service benchmarking
                       12.4.5 Geographic presence
                       12.4.6 Strategic initiatives
                       12.4.7 SWOT
                   12.5 Promedica International
                       12.5.1 Company overview
                       12.5.2 Financial performance
                       12.5.3 Organization structure & team composition
                           12.5.3.1 Team composition
                       12.5.4 Service benchmarking
                       12.5.5 Geographic presence
                       12.5.6 SWOT
                   12.6 WuXi AppTec, Inc.
                       12.6.1 Company overview
                       12.6.2 Financial performance
                       12.6.3 Organization structure & team composition
                           12.6.3.1 Team composition
                       12.6.4 Service benchmarking
                       12.6.5 Geographic presence
                       12.6.6 Strategic initiatives
                       12.6.7 SWOT
                   12.7 Medpace
                       12.7.1 Company overview
                       12.7.2 Financial performance
                       12.7.3 Organization structure & team composition
                           12.7.3.1 Team composition
                       12.7.4 Service benchmarking
                       12.7.5 Geographic presence
                       12.7.6 SWOT
                   12.8 Charles River Laboratories International, Inc.
                       12.8.1 Company overview
                       12.8.2 Financial performance
                       12.8.3 Organization structure & team composition
                           12.8.3.1 Team composition
                       12.8.4 Service benchmarking
                       12.8.5 Geographic presence
                       12.8.6 Strategic initiatives
                       12.8.7 SWOT
                   12.9 ICON plc
                       12.9.1 Company overview
                       12.9.2 Financial performance
                       12.9.3 Organization structure & team composition
                           12.9.3.1 Team composition
                       12.9.4 Service benchmarking
                       12.9.5 Geographic presence
                       12.9.6 Strategic initiatives
                       12.9.7 SWOT
                   12.10 Covance
                       12.10.1 Company overview
                       12.10.2 Financial performance
                       12.10.3 Organization structure & team composition
                           12.10.3.1 Team composition
                       12.10.4 Service benchmarking
                       12.10.5 Geographic presence
                       12.10.6 Strategic initiatives
                       12.10.7 SWOT
                   12.11 PAREXEL International Corporation, Inc.
                       12.11.1 Company overview
                       12.11.2 Financial performance
                       12.11.3 Organization structure & team composition
                           12.11.3.1 Team composition
                       12.11.4 Service benchmarking
                       12.11.5 Geographic presence
                       12.11.6 Strategic initiatives
                       12.11.7 SWOT
                   12.12 Freyr
                       12.12.1 Company overview
                       12.12.2 Financial performance
                       12.12.3 Organization structure & team composition
                           12.12.3.1 Team composition
                       12.12.4 Service benchmarking
                       12.12.5 Geographic presence
                       12.12.6 Strategic initiatives
                       12.12.7 SWOT

List of Tables

Table 1 List of secondary sources
Table 2 List of Abbreviations

List of Figures

Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Regulatory affairs market snapshot (2020)
Fig. 9 Regulatory affairs market segmentation
Fig. 10 Market driver relevance analysis (Current & future impact)
Fig. 11 Number of Trials, By WHO Regions
Fig. 12 Personalized Medicine as a percentage of CDER approved novel molecules.
Fig. 13 Market restraint relevance analysis (Current & future impact)
Fig. 14 Penetration & growth prospect mapping
Fig. 15 SWOT
Fig. 16 Porter’s five forces analysis
Fig. 17 SWOT analysis, by factor (political & legal, economic and technological)
Fig. 18 Regulatory affairs market service outlook: Segment dashboard
Fig. 19 Regulatory affairs market: service movement analysis
Fig. 20 Regulatory consulting market, 2016 - 2028 (USD Million)
Fig. 21 Legal representation market, 2016 - 2028 (USD Million)
Fig. 22 Regulatory writing and publishing market, 2016 - 2028 (USD Million)
Fig. 23 Product registration and clinical trial application market, 2016 - 2028 (USD Million)
Fig. 24 Other regulatory services market, 2016 - 2028 (USD Million)
Fig. 25 Regulatory affairs market service provider outlook: Segment dashboard
Fig. 26 Regulatory affairs market: service provider movement analysis
Fig. 27 In-house regulatory affairs market, 2016 - 2028 (USD Million)
Fig. 28 Outsourcing regulatory affairs market, 2016 - 2028 (USD Million)
Fig. 29 Regulatory affairs market company size outlook: Segment dashboard
Fig. 30 Regulatory affairs market: Company Size movement analysis
Fig. 31 Small companies based regulatory affairs market, 2016 - 2028 (USD Million)
Fig. 32 Medium-sized company based regulatory affairs market, 2016 - 2028 (USD Million)
Fig. 33 Large companies based regulatory affairs market, 2016 - 2028 (USD Million)
Fig. 34 Regulatory affairs market categories outlook: Segment dashboard
Fig. 35 Regulatory affairs market: Categories movement analysis
Fig. 36 Drugs based regulatory affairs market, 2016 - 2028 (USD Million)
Fig. 37 Biologics based regulatory affairs market, 2016 - 2028 (USD Million)
Fig. 38 Medical devices based regulatory affairs market, 2016 - 2028 (USD Million)
Fig. 39 Regulatory affairs product stage outlook: Segment dashboard
Fig. 40 Regulatory affairs market: Product Stage movement analysis
Fig. 41 Preclinical based regulatory affairs market, 2016 - 2028 (USD Million)
Fig. 42 Clinical based regulatory affairs market, 2016 - 2028 (USD Million)
Fig. 43 PMA based regulatory affairs market, 2016 - 2028 (USD Million)
Fig. 44 Regulatory affairs market indication outlook: Segment dashboard
Fig. 45 Regulatory affairs market: indication movement analysis
Fig. 46 Oncology based regulatory affairs market, 2016 - 2028 (USD Million)
Fig. 47 Neurology based regulatory affairs market, 2016 - 2028 (USD Million)
Fig. 48 Cardiology based regulatory affairs market, 2016 - 2028 (USD Million)
Fig. 49 Immunology indication based regulatory affairs market, 2016 - 2028 (USD Million)
Fig. 50 Other indication based regulatory affairs market, 2016 - 2028 (USD Million)
Fig. 51 Regulatory affairs market end-use outlook: Segment dashboard
Fig. 52 Regulatory affairs market: end-use movement analysis
Fig. 53 Medical device companies market, 2016 - 2028 (USD Million)
Fig. 54 Pharmaceutical companies market, 2016 - 2028 (USD Million)
Fig. 55 Biotechnology companies market, 2016 - 2028 (USD Million)
Fig. 56 Regional market: Key takeaways
Fig. 57 Regional outlook, 2020 & 2028
Fig. 58 North America market, 2016 - 2028 (USD Million)
Fig. 59 U.S. market, 2016 - 2028 (USD Million)
Fig. 60 Canada market, 2016 - 2028 (USD Million)
Fig. 61 Europe market, 2016 - 2028 (USD Million)
Fig. 62 U.K. market, 2016 - 2028 (USD Million)
Fig. 63 Germany market, 2016 - 2028 (USD Million)
Fig. 64 France market, 2016 - 2028 (USD Million)
Fig. 65 Italy market, 2016 - 2028 (USD Million)
Fig. 66 Spain market, 2016 - 2028 (USD Million)
Fig. 67 Russia market, 2016 - 2028 (USD Million)
Fig. 68 Turkey market, 2016 - 2028 (USD Million)
Fig. 69 Netherlands market, 2016 - 2028 (USD Million)
Fig. 70 Switzerland market, 2016 - 2028 (USD Million)
Fig. 71 Sweden market, 2016 - 2028 (USD Million)
Fig. 72 Asia Pacific market, 2016 - 2028 (USD Million)
Fig. 73 Japan market, 2016 - 2028 (USD Million)
Fig. 74 China market, 2016 - 2028 (USD Million)
Fig. 75 India market, 2016 - 2028 (USD Million)
Fig. 76 Australia market, 2016 - 2028 (USD Million)
Fig. 77 South Korea market, 2016 - 2028 (USD Million)
Fig. 78 Indonesia market, 2016 - 2028 (USD Million)
Fig. 79 Malaysia market, 2016 - 2028 (USD Million)
Fig. 80 Singapore market, 2016 - 2028 (USD Million)
Fig. 81 Thailand market, 2016 - 2028 (USD Million)
Fig. 82 Taiwan market, 2016 - 2028 (USD Million)
Fig. 83 Latin America market, 2016 - 2028 (USD Million)
Fig. 84 Brazil market, 2016 - 2028 (USD Million)
Fig. 85 Mexico market, 2016 - 2028 (USD Million)
Fig. 86 Argentina market, 2016 - 2028 (USD Million)
Fig. 87 Colombia market, 2016 - 2028 (USD Million)
Fig. 88 Chile market, 2016 - 2028 (USD Million)
Fig. 89 MEA market, 2016 - 2028 (USD Million)
Fig. 90 South Africa market, 2016 - 2028 (USD Million)
Fig. 91 Saudi Arabia market, 2016 - 2028 (USD Million)
Fig. 92 UAE market, 2016 - 2028 (USD Million)
Fig. 93 Egypt market, 2016 - 2028 (USD Million)
Fig. 94 Israel market, 2016 - 2028 (USD Million)
Fig. 95 Organization Structure - Accell Clinical Research, LLC
Fig. 96 SWOT - Accell Clinical Research, LLC
Fig. 97 Organization Structure - Genpact Ltd
Fig. 98 SWOT - Genpact
Fig. 99 Organization Structure - Criterium, Inc.
Fig. 100 SWOT - Criterium, Inc
Fig. 101 Organization Structure - PRA Health Sciences
Fig. 102 SWOT - PRA Health Sciences
Fig. 103 Organization Structure - Promedica International
Fig. 104 SWOT - Promedica International
Fig. 105 Organization Structure -WuXi AppTec
Fig. 106 SWOT - Wuxi AppTec
Fig. 107 Organization Structure - Medpace
Fig. 108 SWOT - Medpace
Fig. 109 Organization Structure - Charles River Laboratories International, Inc.
Fig. 110 SWOT - Charles River Laboratories International, Inc
Fig. 111 Organization Structure - ICON plc
Fig. 112 SWOT - ICON plc
Fig. 113 Organization Structure - Covance, Inc
Fig. 114 SWOT - Covance, Inc
Fig. 115 Organization Structure - PAREXEL International Corporation
Fig. 116 SWOT - PAREXEL International Corporation
Fig. 117 Organization Structure - Freyr
Fig. 118 SWOT - Freyr